The Role of Stem Cell Transplantation for Chronic Myelogenous Leukemia in the 21st Century

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2015 Apr 9

PMID 25852053

Citations 23

Authors

A John Barrett

Sawa Ito

Affiliations

Soon will be listed here.

Abstract

The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell transplantation (SCT). Nevertheless, SCT still remains an option for accelerated/blastic-phase and selected chronic-phase CML. Transplant outcomes can be optimized by peritransplant TKIs, conditioning regimen, BCR-ABL monitoring, and relapse management. Controversies exist in transplant timing, pediatric CML, alternative donors, and economics. SCT continues to serve as a platform of "operational cure" for CML with TKIs and immunotherapies.

Citing Articles

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group.

Giordano U, Piekarska A, Prejzner W, Gil L, Zaucha J, Kujawska J Biomedicines. 2025; 13(1).

PMID: 39857747 PMC: 11759780. DOI: 10.3390/biomedicines13010163.

[Research on the clinical characteristics and prognosis of children with chronic myeloid leukemia in the blast phase].

Zheng F, Lu A, Jia Y, Zuo Y, Zeng H, Jiang Q Zhonghua Xue Ye Xue Za Zhi. 2024; 45(10):931-936.

PMID: 39622757 PMC: 11579757. DOI: 10.3760/cma.j.cn121090-20240130-00045.

An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.

Short N, Senapati J, Jabbour E Curr Hematol Malig Rep. 2023; 18(6):234-242.

PMID: 37651057 PMC: 11804795. DOI: 10.1007/s11899-023-00709-4.

Anti-Cancer Effects of Oxygen-Atom-Modified Derivatives of Wasabi Components on Human Leukemia Cells.

Lin J, Chi C, Huang Y, Tsai T, Chen Y Int J Mol Sci. 2023; 24(7).

PMID: 37047794 PMC: 10095376. DOI: 10.3390/ijms24076823.

Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.

Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A Leukemia. 2023; 37(3):505-517.

PMID: 36707619 PMC: 9991904. DOI: 10.1038/s41375-023-01822-2.

References

Goldman J . The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant. 2013; 19(5):679-80. DOI: 10.1016/j.bbmt.2013.02.016. View

. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013; 121(22):4439-42. PMC: 4190613. DOI: 10.1182/blood-2013-03-490003. View

Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel N, Rabin K . Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013; 27(7):1538-47. PMC: 3867129. DOI: 10.1038/leu.2013.66. View

Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Apperley J . European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872-84. PMC: 4915804. DOI: 10.1182/blood-2013-05-501569. View

Bevans M, Mitchell S, Barrett J, Bishop M, Childs R, Fowler D . Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors. Biol Blood Marrow Transplant. 2013; 20(3):387-95. PMC: 3962950. DOI: 10.1016/j.bbmt.2013.12.001. View

Gill S, Tasian S, Ruella M, Shestova O, Li Y, Porter D . Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014; 123(15):2343-54. PMC: 3983612. DOI: 10.1182/blood-2013-09-529537. View

Jabbour E, Kantarjian H . Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014; 89(5):547-56. DOI: 10.1002/ajh.23691. View

Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M . Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014; 123(25):3951-62. DOI: 10.1182/blood-2013-10-536078. View

Barrett A, Ringden O, Zhang M, Bashey A, Cahn J, Cairo M . Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000; 95(11):3323-7. View

10.

Kantarjian H, OBrien S, Cortes J, Giralt S, Rios M, Shan J . Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002; 100(5):1590-5. View

11.

Or R, Shapira M, Resnick I, Amar A, Ackerstein A, Samuel S . Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2002; 101(2):441-5. DOI: 10.1182/blood-2002-02-0535. View

12.

Das M, Saikia T, Advani S, Parikh P, Tawde S . Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant. 2003; 32(2):125-9. DOI: 10.1038/sj.bmt.1704107. View

13.

Olavarria E, Ottmann O, Deininger M, Clark R, Bandini G, Byrne J . Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2003; 17(9):1707-12. DOI: 10.1038/sj.leu.2403068. View

14.

Ullmann A, Hess G, Kolbe K, Friedrich-Freksa A, Meyer R, Gschaidmeier H . Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation. Keio J Med. 2003; 52(3):182-8. DOI: 10.2302/kjm.52.182. View

15.

Goldman J, Melo J . Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003; 349(15):1451-64. DOI: 10.1056/NEJMra020777. View

16.

Sloand E, Childs R, Solomon S, Greene A, Young N, Barrett A . The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant. 2003; 32(9):897-901. DOI: 10.1038/sj.bmt.1704231. View

17.

Kim Y, Kim D, Lee S, Kim Y, Hwang J, Park Y . Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment. Bone Marrow Transplant. 2003; 33(2):237-42. DOI: 10.1038/sj.bmt.1704332. View

18.

DeAngelo D, Hochberg E, Alyea E, Longtine J, Lee S, Galinsky I . Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host.... Clin Cancer Res. 2004; 10(15):5065-71. DOI: 10.1158/1078-0432.CCR-03-0580. View

19.

Buckner C, Clift R, Fefer A, Neiman P, Storb R, Thomas E . Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol. 1974; 2(3):138-46. View

20.

Buckner C, Stewart P, Clift R, Fefer A, Neiman P, Singer J . Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol. 1978; 6(1):96-109. View